☆ 4.3 Review

SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies

INTERNATIONAL REVIEWS OF IMMUNOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Multidisciplinary Sciences

Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2

Leo Swadling et al.

Summary: Research suggests that some individuals can clear potential SARS-CoV-2 infection after exposure, with T cells playing a role in the process. Studying healthcare workers who tested negative for antibodies revealed that they had stronger and more diverse memory T cells, with a focus on RTC.

NATURE (2022)

Add to Collection

Review Immunology

Tuberculosis vaccine BCG: the magical effect of the old vaccine in the fight against the COVID-19 pandemic

Ashok Aspatwar et al.

Summary: BCG vaccine plays a key role in reducing childhood mortality rates, protecting children against respiratory infections, lowering the risk of malaria, and providing immunity against respiratory infections in elderly people. Additionally, BCG also offers nonspecific innate immunity and has the potential to act as a protective agent against COVID-19.

INTERNATIONAL REVIEWS OF IMMUNOLOGY (2022)

Add to Collection

Article Infectious Diseases

Genomic surveillance to combat COVID-19: challenges and opportunities

Janet Robishaw et al.

Summary: While vaccines offer hope for recovery from the COVID-19 pandemic, genomic surveillance is crucial in detecting and responding to virus variants in a timely manner to mitigate and contain outbreaks effectively.

LANCET MICROBE (2021)

Add to Collection

Article Medicine, General & Internal

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Merryn Voysey et al.

Summary: The ChAdOx1 nCoV-19 vaccine has been shown to have an acceptable safety profile and effectiveness against symptomatic COVID-19, with higher efficacy observed in the group that received a low dose followed by a standard dose.

LANCET (2021)

Add to Collection

News Item Multidisciplinary Sciences

FAST-SPREADING COVID VARIANT CAN ELUDE IMMUNE RESPONSES

Ewen Callaway

NATURE (2021)

Add to Collection

Article Multidisciplinary Sciences

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

Jennifer M. Dan et al.

Summary: Different components of immune memory to SARS-CoV-2 exhibit distinct kinetics, with antibodies and spike-specific memory B cells remaining relatively stable over 6 months, while CD4(+) T cells and CD8(+) T cells declining with a half-life of 3 to 5 months after infection.

SCIENCE (2021)

Add to Collection

Article Multidisciplinary Sciences

SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice

Jing-Hui Tian et al.

Summary: The study reports the development of a SARS-CoV-2 subunit vaccine candidate that contains full-length spike protein stabilized in its prefusion conformation, showing immunogenicity in mice and protection in baboons with Matrix-M adjuvanted vaccine, supporting ongoing phase 1/2 clinical evaluation of NVX-CoV2373 with Matrix-M (NCT04368988).

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Emergence of SARS-CoV-2 B.1.1.7 Lineage — United States, December 29, 2020–January 12, 2021

Summer E. Galloway et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

Add to Collection

Article Microbiology

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines

Xiaoying Shen et al.

Summary: Current COVID-19 vaccines target the ancestral SARS-CoV-2 spike, but the emerging B.1.1.7 variant with multiple spike mutations may impact some antibody therapies while posing no major concerns for vaccine efficacy or increased risk of reinfection.

CELL HOST & MICROBE (2021)

Add to Collection

Article Medicine, General & Internal

SARS-CoV-2 re-infection risk in Austria

Stefan Pilz et al.

Summary: According to the study in Austria, the rate of SARS-CoV-2 re-infections is relatively low. Protection against SARS-CoV-2 after natural infection is comparable to the highest estimates of vaccine efficacies.

EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2021)

Add to Collection

Article Medicine, General & Internal

Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19

Kathryn E. Stephenson et al.

Summary: The study evaluated the immunogenicity of the Ad26.COV2.S vaccine in human participants, showing rapid induction of spike-specific humoral and cellular immune responses. Various antibody subclasses, Fc receptor binding properties, and antiviral functions were induced, along with CD4+ and CD8+ T-cell responses.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Urology & Nephrology

A Novel Soluble ACE2 Variant with Prolonged Duration of Action Neutralizes SARS-CoV-2 Infection in Human Kidney Organoids

Jan Wysocki et al.

Summary: A novel ACE2 variant has been developed that can neutralize SARS-CoV-2 infectivity in human kidney organoids, with prolonged duration of action and potential for improved efficacy.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2021)

Add to Collection

Review Medicine, General & Internal

Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment

Olivier J. Wouters et al.

Summary: The COVID-19 pandemic may not end globally until vaccines that protect against severe disease and drive herd immunity are widely distributed. While vaccines have been authorized for human use in many countries, achieving global control of COVID-19 requires not only licensed vaccines but also mass production, affordable pricing, global allocation, and wide local deployment.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Merryn Voysey et al.

Summary: The AZD1222 vaccine has been approved for emergency use in the UK with an interval of 4-12 weeks between doses. Analysis shows that the vaccine is efficacious with two doses and provides immunoprotection after the first dose before the second dose is administered.

LANCET (2021)

Add to Collection

Editorial Material Medicine, General & Internal

Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence

Ester C. Sabino et al.

LANCET (2021)

Add to Collection

Article Multidisciplinary Sciences

Furin cleavage of the SARS-CoV-2 spike is modulated by O-glycosylation

Liping Zhang et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)

Add to Collection

Article Multidisciplinary Sciences

Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies

Dami A. Collier et al.

Summary: The B.1.1.7 variant of SARS-CoV-2 exhibited reduced neutralization by vaccines and antibodies from recovered COVID-19 patients, with a more substantial loss seen when introducing the E484K mutation. This mutation poses a threat to the efficacy of the BNT162b2 vaccine.

NATURE (2021)

Add to Collection

News Item Multidisciplinary Sciences

The coronavirus is here to stay - here's what that means

Nicky Phillips

Summary: Scientists expect the virus that causes COVID-19 to become endemic and pose less danger over time, according to a Nature survey.

NATURE (2021)

Add to Collection

Article Multidisciplinary Sciences

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

Pengfei Wang et al.

Summary: The COVID-19 pandemic has had global repercussions, with promising vaccines and monoclonal antibody therapies. However, newly detected variants of SARS-CoV-2 present challenges to these treatment options.

NATURE (2021)

Add to Collection

Letter Biotechnology & Applied Microbiology

Could mutations of SARS-CoV-2 suppress diagnostic detection?

Carl A. Ascoli

NATURE BIOTECHNOLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

Early lab studies shed light on Omicron’s behavior

Gretchen Vogel et al.

SCIENCE (2021)

Add to Collection

Letter Nursing

The commitment for fair distribution of COVID-19 vaccine among all countries of the world

Reza Sadeghi et al.

RESEARCH IN NURSING & HEALTH (2021)

Add to Collection

Article Multidisciplinary Sciences

Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England

Nicholas G. Davies et al.

Summary: A new variant of SARS-CoV-2 has emerged in England, with a higher reproduction number and potential for large resurgences of COVID-19 cases. Without stringent control measures, it is projected that COVID-19 hospitalizations and deaths in England for the first 6 months of 2021 will exceed those in 2020. The variant has spread globally and exhibited similar transmission increases in Denmark, Switzerland, and the United States.

SCIENCE (2021)

Add to Collection

Article Virology

Inhibitors of endosomal acidification suppress SARS-CoV-2 replication and relieve viral pneumonia in hACE2 transgenic mice

Chao Shang et al.

Summary: This study found that endosomal acidification inhibitors, including chloroquine, bafilomycin A1, and NH4Cl, significantly reduced the viral yields of SARS-CoV-2 in various cell lines and in a transgenic mouse model. These inhibitors also improved cell viability post-infection and alleviated viral pneumonia in mice, suggesting potential therapeutic benefits in treating COVID-19.

VIROLOGY JOURNAL (2021)

Add to Collection

News Item Medicine, General & Internal

Covid-19: WHO warns against vaccine nationalism or face further virus mutations

Lynn Eaton

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

News Item Medicine, General & Internal

Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant

Elisabeth Mahase

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

Article Multidisciplinary Sciences

Targeting androgen regulation of TMPRSS2 and ACE2 as a therapeutic strategy to combat COVID-19

Qu Deng et al.

Summary: The study suggests a potential role of androgen in SARS-CoV-2 infection by regulating ACE2 and TMPRSS2 transcription. Camostat, a TMPRSS2 inhibitor, blocks the cleavage of SARS-CoV-2 Spike protein, providing evidence of TMPRSS2's direct role in viral fusion to host cells. Androgen-deprivation, anti-androgens, or camostat attenuate SARS-CoV-2 cellular entry, highlighting the importance of TMPRSS2 inhibitors and androgen-deprivation therapy in preventing COVID-19 progression.

ISCIENCE (2021)

Add to Collection

News Item Medicine, General & Internal

Covid-19: Omicron may be more transmissible than other variants and partly resistant to existing vaccines, scientists fear

Ingrid Torjesen

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

News Item Medicine, General & Internal

Covid-19: Hospital admission 50-70% less likely with omicron than delta, but transmission a major concern

Elisabeth Mahase

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant

Xianding Deng et al.

Summary: A new SARS-CoV-2 variant named B.1.427/B.1.429 was identified in California, with increased transmissibility and carrying three mutations in spike protein, including L452R substitution. The variant emerged in May 2020 and became predominant in sequenced cases from September 2020 to January 2021. In vivo viral shedding was increased and antibody neutralization decreased, calling for further investigation.

CELL (2021)

Add to Collection

Article Microbiology

Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization

Pengfei Wang et al.

Summary: The emerging Brazilian variant P.1 shows increased resistance to antibody neutralization, posing a threat to current antibody therapies, but has less impact on the effectiveness of protective vaccines.

CELL HOST & MICROBE (2021)

Add to Collection

Editorial Material Medicine, General & Internal

The Potential Future of the COVID-19 Pandemic Will SARS-CoV-2 Become a Recurrent Seasonal Infection?

Christopher J. L. Murray et al.

Summary: The viewpoint discusses the possibility of COVID-19 becoming a seasonal disease like influenza and suggests strategies to mitigate the consequences for communities and health systems, including changes in surveillance methods, medical and public health responses, and socioeconomic programs.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Cell Biology

Higher infectivity of the SARS-CoV-2 new variants is associated with K417N/T, E484K, and N501Y mutants: An insight from structural data

Abbas Khan et al.

Summary: The new variants of SARS-CoV-2 are more contagious and require further investigation on their interaction with the host receptor to identify new therapeutic options. Specific mutations in the Spike glycoprotein of the new variants may play a critical role in their unique pathogenicity.

JOURNAL OF CELLULAR PHYSIOLOGY (2021)

Add to Collection

Article Public, Environmental & Occupational Health

The Disease Severity and Clinical Outcomes of the SARS-CoV-2 Variants of Concern

Lixin Lin et al.

Summary: Studies have shown that Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2 have increased severity in terms of hospitalization, ICU admission, and mortality compared to the wild-type virus, with Beta and Delta variants posing higher risks.

FRONTIERS IN PUBLIC HEALTH (2021)

Add to Collection

Article Medicine, General & Internal

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

Katherine R. W. Emary et al.

Summary: A post-hoc analysis was conducted on the efficacy of the ChAdOx1 nCoV-19 vaccine against the B.1.1.7 variant of SARS-CoV-2 in the UK. The vaccine showed reduced neutralisation activity against the B.1.1.7 variant in vitro, but still demonstrated efficacy against the B.1.1.7 variant of the virus.

LANCET (2021)

Add to Collection

Article Multidisciplinary Sciences

‘Unprecedented achievement’: who received the first billion COVID vaccinations?

Freda Kreier

NATURE (2021)

Add to Collection

Article Medicine, General & Internal

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

S. A. Madhi et al.

Summary: The ChAdOx1 nCoV-19 vaccine did not provide significant protection against mild-to-moderate Covid-19 caused by the B.1.351 variant, with an efficacy of 10.4%. The incidence of serious adverse events was balanced between the vaccine and placebo groups.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant

V. Shinde et al.

Summary: The NVX-CoV2373 vaccine showed efficacy in preventing Covid-19, with higher vaccine efficacy observed among HIV-negative participants. Most infections were caused by the B.1.351 variant.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Biology

New challenges to fighting COVID-19: Virus variants, potential vaccines, and development of antivirals

Jun Chen et al.

Summary: Despite strict control measures, the COVID-19 pandemic continues to rage globally. Scientists are encouraging herd immunity, highlighting the precarious nature of immunity generated after natural infection. Vaccines are considered the most promising approach to return to normality, but concerns remain regarding their accessibility, vaccination rate, and efficacy against emerging virus variants.

BIOSCIENCE TRENDS (2021)

Add to Collection

Review Immunology

COVID-19 Vaccines: Current Understanding on Immunogenicity, Safety, and Further Considerations

Qian He et al.

Summary: The world is facing the second wave of the COVID-19 pandemic, with a higher intensity than the first wave of early 2020. Multiple COVID-19 vaccine candidates have been developed and are undergoing clinical testing to rapidly respond to the global pandemic. Evaluating and defining effective vaccine candidates is crucial for prioritizing vaccination programs against COVID-19.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Review Medicine, General & Internal

Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines

Bogdan Doroftei et al.

Summary: After analyzing 19 relevant articles, it was concluded that among the eleven vaccines, Pfizer-BioNTech (about 95%), Moderna (about 94%), and Sputnik V (about 92%) showed an efficacy greater than 90%, while Oxford-AstraZeneca was only about 81% effective. Additionally, Moderna, Sputnik V, and Oxford-AstraZeneca also reduced the occurrence of severe adverse reactions.

DIAGNOSTICS (2021)

Add to Collection

Review Immunology

COVID-19 pandemic: SARS-CoV-2 specific vaccines and challenges, protection via BCG trained immunity, and clinical trials

Wenping Gong et al.

Summary: This study reviewed the concept and mechanisms of trained immunity induced by the BCG vaccine and presented details of current BCG vaccine clinical trials. The advantages of the BCG vaccine may be essential in overcoming the challenges faced by COVID-19 vaccines.

EXPERT REVIEW OF VACCINES (2021)

Add to Collection

Article Microbiology

Acquisition of the L452R Mutation in the ACE2-Binding Interface of Spike Protein Triggers Recent Massive Expansion of SARS-CoV-2 Variants

Veronika Tchesnokova et al.

Summary: A recent global expansion of various independent SARS-CoV-2 variants with mutation L452R in the spike protein's receptor-binding domain has been reported. The emergence of these variants, including epsilon, delta, kappa, iota, and lambda, has been associated with increased viral transmissibility, infectivity, and pathogenicity due to the L452R mutation near the ACE2 interaction interface.

JOURNAL OF CLINICAL MICROBIOLOGY (2021)

Add to Collection

Letter Medicine, General & Internal

Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination

Emma C. Wall et al.

LANCET (2021)

Add to Collection

Letter Infectious Diseases

The SARS-CoV-2 B.1.1.7 variant and increased clinical severity-the jury is out

Benjamin Giles et al.

Summary: The information above covers topics such as clotting issues after COVID-19 vaccination, comparing immunogenicity between different vaccines, and the relationship between neutralizing antibodies and protection from SARS-CoV-2 infection.

LANCET INFECTIOUS DISEASES (2021)

Add to Collection

Article Infectious Diseases

Mortality and critical care unit admission associated with the SARS-CoV-2 lineage B.1.1.7 in England: an observational cohort study

Martina Patone et al.

Summary: This study analyzed the clinical outcomes of patients infected with the new SARS-CoV-2 lineage B.1.1.7 compared to non-B.1.1.7 infections, finding that patients with B.1.1.7 were more likely to be admitted to critical care units and die within 28 days. However, for patients receiving critical care, mortality seemed to be independent of the virus strain.

LANCET INFECTIOUS DISEASES (2021)

Add to Collection

Article Multidisciplinary Sciences

Highly accurate protein structure prediction with AlphaFold

John Jumper et al.

Summary: Proteins are essential for life, and accurate prediction of their structures is a crucial research problem. Current experimental methods are time-consuming, highlighting the need for accurate computational approaches to address the gap in structural coverage. Despite recent progress, existing methods fall short of atomic accuracy in protein structure prediction.

NATURE (2021)

Add to Collection

Review Biochemistry & Molecular Biology

The next phase of SARS-CoV-2 surveillance: real-time molecular epidemiology

Bas B. Oude Munnink et al.

Summary: This review summarizes the current knowledge on key viral mutations and variants, emphasizing the need for a systematic approach to link global genomic surveillance with timely assessment of the phenotypic characteristics of novel variants in preparation for the next phase of the pandemic.

NATURE MEDICINE (2021)

Add to Collection

Editorial Material Biochemistry & Molecular Biology

Understanding COVID-19 vaccine hesitancy

Shingai Machingaidze et al.

Summary: The new study reveals the complexities of COVID-19 vaccine hesitancy and acceptance in low-, middle-, and high-income countries.

NATURE MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents

Robert W. Frenck et al.

Summary: The BNT162b2 vaccine showed favorable safety profile and a greater immune response in 12-to-15-year-old recipients compared to young adults, and demonstrated high effectiveness against Covid-19.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine

Paul T. Heath et al.

Summary: The NVX-CoV2373 vaccine demonstrated an efficacy of 89.7% in a phase 3 trial with over 15,000 participants, with mild and transient reactogenicity. It showed high efficacy against the B.1.1.7 variant and a low incidence of adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Review Microbiology

New variants of SARS-CoV-2

Rafael Canton et al.

Summary: The emergence and spread of new variants of SARS-CoV-2 have raised concerns over their potential impact on virus transmission, individual infection evolution, and vaccine immunity escape. Countries worldwide need to increase vaccination rates and maintain epidemiological measures to prevent the spread of these variants.

REVISTA ESPANOLA DE QUIMIOTERAPIA (2021)

Add to Collection

News Item Medicine, General & Internal

Covid-19: Local councils initiate surge vaccination to tackle B.1.617.2 variant

Gareth Iacobucci

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

Article Biotechnology & Applied Microbiology

Effectiveness of booster BCG vaccination in preventing Covid-19 infection

Lradj Amirlak et al.

Summary: The study found that no cases of COVID-19 infection were detected among employees who received the booster BCG vaccine, compared to 18 positive cases in the unvaccinated group. This suggests the potential effectiveness of the booster BCG vaccine in preventing COVID-19 infections in a high-risk healthcare population.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2021)

Add to Collection

Article Public, Environmental & Occupational Health

SARS-CoV-2 B.1.617.2 (Delta) Variant COVID-19 Outbreak Associated with a Gymnastics Facility — Oklahoma, April–May 2021

Kendra Dougherty et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

Add to Collection

Article Microbiology

SARS-CoV-2 Spike Mutations, L452R, T478K, E484Q and P681R, in the Second Wave of COVID-19 in Maharashtra, India

Sarah Cherian et al.

Summary: Genomic epidemiology and whole genome sequencing were used to investigate the transmission and evolution of the SARS-CoV-2 virus during the global pandemic. The study identified new variants B.1.617.1 and B.1.617.2 in India, responsible for the second wave of COVID-19 in Maharashtra, with B.1.617.2 designated as a VOC delta and B.1.617.1 as a variant of interest kappa. Monitoring of these and emerging variants in India is crucial for public health.

MICROORGANISMS (2021)

Add to Collection

Article Medicine, General & Internal

Severe SARS-CoV-2 Breakthrough Reinfection With Delta Variant After Recovery From Breakthrough Infection by Alpha Variant in a Fully Vaccinated Health Worker

Jayanthi Shastri et al.

Summary: The study found that despite post-vaccination immunity and immunity acquired through past infection, breakthrough infections caused by Variants of Concern can still occur in COVID-19 cases. A patient in the study experienced breakthrough infections with the Alpha variant and the Delta variant, the latter resulting in severe illness even after boosting. The source of infection was established through clinical data and genetic sequencing.

FRONTIERS IN MEDICINE (2021)

Add to Collection

Article Zoology

Emerging SARS-CoV-2 B.1.621/Mu variant is prominently resistant to inactivated vaccine-elicited antibodies

Xiaochun Xie et al.

ZOOLOGICAL RESEARCH (2021)

Add to Collection

Letter Immunology

Confirmed Reinfection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variant VOC-202012/01

David Harrington et al.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Article Health Care Sciences & Services

Impact of original, B.1.1.7, and B.1.351/P.1 SARS-CoV-2 lineages on vaccine effectiveness of two doses of COVID-19 mRNA vaccines: Results from a nationwide case-control study in France

Tiffany Charmet et al.

Summary: The study found that in real-life settings, two doses of mRNA vaccines were effective against COVID-19 with the original virus, B.1.1.7 lineage, and B.1.351/P.1 lineages.

LANCET REGIONAL HEALTH-EUROPE (2021)

Add to Collection

Article Health Care Sciences & Services

A look into the future of the COVID-19 pandemic in Europe: an expert consultation

Emil Nafis Iftekhar et al.

Summary: The future development of the COVID-19 pandemic will be influenced by the progress of national and global vaccination programs, the emergence and spread of variants of concern, and public responses to non-pharmaceutical interventions. Challenges include the risk of lifting restrictions too early, potential resurgence of transmission due to increased indoor activity, and the possibility of intensive care units reaching capacity if vaccination levels remain low.

LANCET REGIONAL HEALTH-EUROPE (2021)

Add to Collection

Article Multidisciplinary Sciences

SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion

Petra Mlcochova et al.

Summary: The B.1.617.2 (Delta) variant of SARS-CoV-2 has lower sensitivity to antibodies and higher replication efficiency compared to other lineages, which may contribute to its dominance and reduced vaccine effectiveness, highlighting the need for continued infection control measures post-vaccination.

NATURE (2021)

Add to Collection

Article Immunology

Serosurvey in BNT162b2 vaccine-elicited neutralizing antibodies against authentic B.1, B.1.1.7, B.1.351, B.1.525 and P.1 SARS-CoV-2 variants

Alberto Zani et al.

Summary: The study demonstrates that antibodies generated by the BNT162b2 vaccine can efficiently neutralize authentic viruses belonging to various SARS-CoV-2 lineages. Neutralization was highest for B.1.1.7 and B.1.525 lineages, while lower for B.1.351 and P.1 lineages compared to the B.1 lineage. The findings suggest that the BNT162b2 vaccine offers protection against the prevailing variants of SARS-CoV-2.

EMERGING MICROBES & INFECTIONS (2021)

Add to Collection

Review Critical Care Medicine

Emerging SARS-CoV-2 variants of concern and potential intervention approaches

Jasmin Khateeb et al.

Summary: Mutations in VOCs can increase the transmissibility of the virus and potentially impact vaccine efficacy, highlighting the need for combination therapeutic strategies.

CRITICAL CARE (2021)

Add to Collection

Letter Infectious Diseases

SARS-CoV-2 spike E484K mutation reduces antibody neutralisation

Sonia Jangra et al.

LANCET MICROBE (2021)

Add to Collection

Review Medicine, General & Internal

Will Mutations in the Spike Protein of SARS-CoV-2 Lead to the Failure of COVID-19 Vaccines?

Zaixing Jia et al.

Summary: SARS-CoV-2 has caused a global pandemic since its discovery, leading to the emergence of variants with common N501Y mutations that may impact viral fitness and transmission, although the effects on COVID-19 vaccines remain unknown.

JOURNAL OF KOREAN MEDICAL SCIENCE (2021)

Add to Collection

Article Multidisciplinary Sciences

Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans

Bas B. Oude Munnink et al.

Summary: Animal experiments have shown that various animals can be infected by SARS-CoV-2, with evidence of animal-to-human transmission within mink farms. Investigation into mink farm outbreaks revealed that the virus was initially introduced by humans and has since evolved, causing transmission between mink farms. Despite enhanced biosecurity measures and culling, transmission occurred between farms in three large clusters with unknown modes of transmission, resulting in a high percentage of infections among mink farm residents and employees.

SCIENCE (2021)

Add to Collection

Review Immunology

Viral targets for vaccines against COVID-19

Lianpan Dai et al.

Summary: The urgent need for vaccines to control the COVID-19 pandemic has led to the rapid development of multiple vaccine candidates, with some showing positive results in late-stage clinical trials. This article discusses the viral elements used in these candidates, the reasons why they are good targets for the immune system, and their implications for protective immunity. Dai and Gao highlight the importance of selecting the right viral targets in vaccine development to ensure an effective immune response and the overall safety and efficacy of the vaccine.

NATURE REVIEWS IMMUNOLOGY (2021)

Add to Collection

Review Immunology

Comparison of the immunogenicity & protective efficacy of various SARS-CoV-2 vaccine candidates in non-human primates

Labanya Mukhopadhyay et al.

Summary: This systematic review compared the immunogenicity and protective efficacy of various SARS-CoV-2 vaccine candidates tested in non-human primate (NHP) models. Results showed that most vaccines induced detectable neutralizing antibodies and had some effectiveness in viral clearance. Some vaccines demonstrated better immunogenicity and protective efficacy in NHP models compared to others.

INDIAN JOURNAL OF MEDICAL RESEARCH (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza

Timothy R. Abbott et al.

CELL (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Alexandra C. Walls et al.

CELL (2020)

Add to Collection

Review Immunology

SARS-CoV-2 Vaccines: Status Report

Fatima Amanat et al.

IMMUNITY (2020)

Add to Collection

Review Medicine, General & Internal

Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19) A Review

James M. Sanders et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Editorial Material Medicine, General & Internal

Developing Covid-19 Vaccines at Pandemic Speed

Nicole Lurie et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Biochemistry & Molecular Biology

The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity

Qianqian Li et al.

CELL (2020)

Add to Collection

Review Microbiology

Evidence for SARS-CoV-2 Infection of Animal Hosts

Ahmed S. Abdel-Moneim et al.

PATHOGENS (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Mutations Strengthened SARS-CoV-2 Infectivity

Jiahui Chen et al.

JOURNAL OF MOLECULAR BIOLOGY (2020)

Add to Collection

Article Multidisciplinary Sciences

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies

Alina Baum et al.

SCIENCE (2020)

Add to Collection

Article Medicine, General & Internal

Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

Cheryl Keech et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Multidisciplinary Sciences

REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters

Alina Baum et al.

SCIENCE (2020)

Add to Collection

Article Immunology

NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge

Mimi Guebre-Xabier et al.

VACCINE (2020)

Add to Collection

Article

Is the tuberculosis vaccine BCG an alternative weapon for developing countries to defeat COVID-19?

Wenping Gong et al.

Indian Journal of Tuberculosis (2020)

Add to Collection

Article Biology

Latest updates on COVID-19 vaccines

Qian Li et al.

BIOSCIENCE TRENDS (2020)

Add to Collection

Article Multidisciplinary Sciences

Robust neutralizing antibodies to SARS-CoV-2 infection persist for months

Ania Wajnberg et al.

SCIENCE (2020)

Add to Collection

Article Immunology

Vaccine hesitancy: Definition, scope and determinants

Noni E. MacDonald

VACCINE (2015)

Add to Collection

Article Microbiology

Newly Emerging Mutations in the Matrix Genes of the Human Influenza A(H1N1)pdm09 and A(H3N2) Viruses Reduce the Detection Sensitivity of Real-Time Reverse Transcription-PCR

Ji-Rong Yang et al.

JOURNAL OF CLINICAL MICROBIOLOGY (2014)

Add to Collection

© Peeref 2019-2024. All rights reserved.